Ernexa Therapeutics (NASDAQ:ERNA) Announces Quarterly Earnings Results, Misses Expectations By $5.00 EPS

Ernexa Therapeutics (NASDAQ:ERNA) announced its quarterly earnings data on Wednesday. The company reported ($6.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($5.00), FiscalAI reports.

Ernexa Therapeutics Price Performance

Ernexa Therapeutics stock opened at $12.46 on Friday. The firm has a 50 day simple moving average of $6.62 and a 200-day simple moving average of $19.46. Ernexa Therapeutics has a 1-year low of $3.18 and a 1-year high of $91.54. The stock has a market cap of $14.53 million, a price-to-earnings ratio of -0.48 and a beta of 1.88.

Hedge Funds Weigh In On Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned about 0.39% of Ernexa Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 70.55% of the company’s stock.

Wall Street Analysts Forecast Growth

ERNA has been the subject of several research reports. Brookline Capital Markets initiated coverage on shares of Ernexa Therapeutics in a research note on Thursday, May 7th. They set a “buy” rating and a $30.00 price objective for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Ernexa Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Finally, Zacks Research raised shares of Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Ernexa Therapeutics currently has an average rating of “Hold” and an average target price of $30.00.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.